drugset
drugset / Trial / NCT00031148

Keratinocyte Growth Factor to Prevent Acute GVHD

NCT00031148 ↗

Phase 1/2 Completed 72 enrolled FDA Office of Orphan Products Development
RandomizedDouble-blindPrevention

Summary

This is a study to determine the safety and efficacy of keratinocyte growth factor (KGF) to prevent acute graft-versus-host disease (GVHD) in patients undergoing allogeneic bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplantation.

Timeline

Start
2001-09
Primary completion
—
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Palifermin Protein / enzyme biologic — —

Indications

acute graft versus host disease